HMBeaconNCT07575308
HMBeacon: A Phase 2 Study to Evaluate ALN-6400 in Adult and Adolescent Female Patients With VWD and HMB
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 8 versions: 8 with changes below. See every version on ClinicalTrials.gov ↗
- Minor Trial sites expanded: 21 → 29 locations
- Minor Trial sites expanded: 11 → 21 locations
- Study completion pushed from Nov 29, 2028 to Aug 30, 2029
- Notable Eligibility criteria expanded, about 8 words
- Trial sites expanded: 4 → 11 locations
- Notable Recruitment opened
- Trial sites expanded: 1 → 4 locations
- Start date changed from estimate of Jul 31, 2026 to Jul 30, 2026
- Notable Start date: Jun 30, 2026 to Jul 31, 2026v4
Show 2 earlier versionsHide 2 earlier versions
- Notable Start date: May 22, 2026 to Jun 30, 2026v3
- Minor Start date: May 5, 2026 to May 22, 2026v2
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Frequency of Adverse Events
Timeframe: Up to Week 72
Secondary (5)
Change from Baseline in Plasminogen (PLG) Plasma Activity Levels
Change from Baseline in PLG Plasma Protein Levels
Change from Baseline in Menstrual Blood Loss Via Pictorial Blood Assessment Chart (PBAC)
Patient-reported Outcome (PRO) assessed by Patient Global Impression of Change (PGI-C) Score
Change from Baseline in PRO assessed by Patient Global Impression of Severity (PGI-S) Score
Arms and interventions
ALN-6400 (Treatment Group A)Experimental
Participants will be administered multiple doses of ALN-6400.
ALN-6400 (Treatment Group B)Experimental
Participants will be administered multiple doses of ALN-6400.
Drugs: ALN-6400
Sites
29 sites in 6 countries
United States 10, United Kingdom 7, Turkey (Türkiye) 5, Germany 4, Netherlands 2, Sweden 1